The threshold used to call a test positive is part of the test's evidence. A cutoff selected because it looked best in one dataset needs evaluation beyond that same dataset.
The primary Cutoff Finder study demonstrated methods that optimize biomarker thresholds against distributions, outcomes or survival. Such an optimized split is a discovery result. Its performance must retain the selection procedure and be assessed with appropriate independent evaluation before a clinical rule is claimed. The assay scale and intended decision also matter: a threshold chosen for one drug or purpose is not automatically transferable to another.
Shares Prognostic and predictive biomarkers, Evidence from measurement to patient benefit, Biomarker.
Shares Evidence from measurement to patient benefit, Biomarker.
Shares Data leakage in model evaluation, External validation.
Shares External validation, Evidence from measurement to patient benefit.
Shares Data leakage in model evaluation, External validation.
Shares Data leakage in model evaluation, External validation.
Shares Data leakage in model evaluation, External validation.
Shares External validation, Evidence from measurement to patient benefit.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/